CFO William Peters Buys 58,693 RSUs on Amphastar: A Bullish Bet Amid a Sliding Stock Price

Insider Activity Spotlight: CFO William J. Peters Buys in a Bullish Move

On March 9, 2026, Amphastar Pharmaceuticals’ chief financial officer, William J. Peters, executed a sizable purchase of 58,693 shares of common stock, paying $0.00 per share because the shares were issued as restricted stock units (RSUs) that vest over four years. The transaction brought his post‑transaction holdings to 180,333 shares, a significant increase from the 121,640 shares he held after a recent sale on March 6. This move follows a pattern of relatively modest selling in early March—two sales totaling 3,890 shares that reduced his stake to 121,640—and is accompanied by a related derivative transaction where he acquired 121,071 shares of employee stock options on the same day. The simultaneous buying of shares and options signals a bullish stance on the company’s future, as the CFO is locking in both current equity and future upside.

What Does This Mean for Investors?

The CFO’s action occurs against a backdrop of a stock that has trended sharply lower over the past year, sliding 28.47% year‑to‑date and posting a weekly decline of almost 6%. Yet the market has responded positively to the insider buying, reflected in a +41 sentiment score on social platforms and a 70.88 % buzz level—well above the 100 % average—suggesting that traders see value in the CFO’s confidence. If the share price continues to recover toward its 52‑week high of $31.26, the CFO’s equity position could deliver substantial gains, reinforcing a narrative that the company’s pipeline and cost‑control measures are beginning to pay off. Conversely, if the stock remains stuck near its low of $18.52, the insider purchase may be perceived as a defensive bet, potentially dampening investor enthusiasm.

Peters’ Historical Insider Profile

Peters has been a consistent, albeit cautious, participant in Amphastar’s insider trading. Over the past year, his activity has been dominated by modest sell‑offs—two transactions in March that totalled 3,890 shares—followed by a large RSU‑based purchase on March 9. Compared to peers such as CEO Jack Y. Zhang, who executed multi‑hundred‑thousand‑share buy/sell cycles, Peters’ moves are relatively conservative and tightly linked to vesting schedules. His pattern of buying RSUs and exercising options rather than outright stock purchases suggests a long‑term commitment, likely aimed at aligning his interests with shareholders over a multi‑year horizon. This disciplined approach may appeal to value‑oriented investors seeking a CFO who demonstrates patience and confidence in the company’s long‑term strategy.

Implications for Amphastar’s Future

The CFO’s recent buying, coupled with a sizable option grant, indicates an expectation of upside in Amphastar’s generic and proprietary drug lines. The company’s focus on injectable and inhalable products, combined with its moderate P/E ratio of 9.8, positions it as a potentially undervalued player in a crowded pharma landscape. If the company can maintain or accelerate its product pipeline and control costs, the insider optimism could translate into a breakout above the current $18.91 close, benefiting all shareholders. Investors should monitor subsequent trading sessions for signs of price momentum and the CFO’s continued equity activity, which may serve as a barometer for corporate confidence.

Bottom Line for Financial Professionals

Insider buying by a key executive is a classic signal of confidence, especially when tied to RSUs and options that lock in future performance. For Amphastar, William J. Peters’ recent purchase suggests that the CFO foresees a rebound in share price, potentially driven by product development and operational efficiencies. While the stock remains volatile, the bullish insider action and positive social sentiment provide a compelling narrative for investors looking to gauge the company’s trajectory in a challenging healthcare market.